Cutaneous melanoma: cost of illness under Brazilian health system perspectives.

ABSTRACT:

Background

The landscape of cutaneous melanoma (CM) diagnosis, staging, prognosis, and treatment has undergone fundamental changes in the past decade. While the benefits of new health resources are recognized, there is a distinct lack of accurate cost-of-illness information to aid healthcare decision makers.

Methods

The cost-of-illness study for CM was conducted from the perspective of two health systems in Brazil: the public health system (Unified Health System, SUS) and the private health system (Health Management Organization, HMO). The study considered the direct medical cost in a bottom-up analysis, using melanoma incidence, knowledge of the disease's progression, and the overall survival rates. The executional costs for the complete healthcare delivery cycle were inves

SUBMITTER: da Veiga CRP 

PROVIDER: S-EPMC8008665 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature